Background: The impact of an episode of hyperkalemia on long term mortality is not well studied. Such a study is vital for development of a utilization strategy for new drugs for the treatment of hyperkalemia. To study the long term impact of hyperkalemia on mortality, we conducted a retrospective, observational casecontrol study in a tertiary care emergency department. We compared cases of non-hemolyzed serum potassium >5.3 mEq/L with normokalemic controls. Allcause mortality and causes of death were determined from social security death index, national death index, and medical record review over a follow-up period of 490 patient years.
Introduction
Hyperkalemia is a potentially lethal electrolyte disorder present in 3.2% of inpatients in a large case series [1] . The increasing prevalence of chronic kidney disease (CKD), end stage renal disease (ESRD), diabetes mellitus (DM), use of angiotensin converting enzyme inhibitors (ACEi) [2] and aldosterone blockers will continue to escalate the burden of hyperkalemia [3, 4] .
The recent development of two new therapies to treat hyperkalemia, sodium zirconium cyclosilicate [5] which demonstrated significant reduction in potassium at 48 hours and maintenance of normokalemia during 12 days. Patiromer also showed a longer term decrease in serum potassium levels in 4 weeks and reduction in recurrence of hyperkalemia over subsequent 8 weeks [6] . It is notable that both studies did not include mortality end points.
Unfortunately, there is a knowledge gap in current literature on the long term effect of hyperkalemia of mortality especially in a generally representative population such as emergency department subjects. A study on the long term morality impact 2 This article is available from: www.archivesofmedicine.com
ARCHIVES OF MEDICINE ISSN 1989-5216
of hyperkalemia is vital for evolution of utilization strategies for new drugs; especially patriromer which showed longer term decrease in potassium levels over 12 weeks [6] . The paucity of existing data on long term mortality in hyperkalemia precludes the accurate future assessment of mortality benefits of these new drugs. Most published literature focuses on the effects of hyperkalemia on short-term mortality [1, 7] . There is a paucity of published literature on the outcomes of hyperkalemia in survivors from the index episode.
Our study aims to address the knowledge gap on longer term mortality effects of hyperkalemia.
We conducted a retrospective, case-control study of hyperkalemic patients who presented to a tertiary care emergency department (ED). The principal aim was to study the predictors of both 1-year and long term all-cause mortality in hyperkalemia. The secondary aim was to study the causes of death in hyperkalemia with a focus on cardiovascular mortality.
Methods

Study sample
We examined a retrospective, observational, unmatched case-control design to study ED patients with hyperkalemia (initial serum K + value >5.3 mEq/L). The cases were comprised of consecutive ED patients in the University of Massachusetts medical system from January 1, 2009 through March 31, 2009 with true hyperkalemia. Controls were identified from the same setting of ED patients, but were ultimately found to have pseudohyperkalemia (hemolyzed blood samples) and were demonstrated to be normokalemic. Patients were excluded when hemolysis could not be reliably excluded (Appendix I).
The study was approved by the Institutional Review Board at the University of Massachusetts Medical School.
Outcomes
The primary endpoint was all-cause mortality determined by searching Social Security Death Index (SSDI) [8] , national death index (NDI), and review of medical records. SSDI data was updated through April 2012. Patients not found in SSDI data were considered alive through January 1, 2012. If there was a conflict, the later date of either SSDI or manual chart review was used as the censoring date in follow-up time calculation. The causes of death were coded per ICD 9 and 10 were obtained from NDI, and manual review of medical records. We analyzed causes of death as determined by international classification of disease (ICD) codes in NDI database or chart review. We postulated that hyperkalemia contributes to arrhythmic or cardiovascular causes of death, and thus categorized patients as having a cardiac versus non-cardiac cause of death. The definition used for cardiac cause of death was ICD 10 codes I00 to I09, I11, I20 to I51, Q20 to Q24, and R95 to R99) [9] or ICD-9-CM codes 410-414 [10] .
Variables
Raw and standardized potassium, as well as a three-level ordinal variable created using cut-points of <5.3, 5.3-6.0, and >6.0 (mEq/L) were analyzed. A four-level ordinal variable for eGFR was also created using the following cut-points: <14.99, 15.00-29.99, 30.00-59.99 and >60.00 (ml/min/1.73 m 2 ). Data on past medical history, medications, treatment, repeat admissions/emergency room visits, follow-up potassium, and creatinine/eGFR were obtained via manual chart review. eGFR was computed per isotope dilution mass spectrometry traceable-modified diet in renal disease (IDMS-MDRD) [11] (Equation 1 Appendix).
Charlson comorbidity index (CCI) [12] , validated in ESRD, HF, critical care and cancer patients [13] , was used to evaluate the chronic disease burden of subjects. CCI can be used to calculate the likelihood of 1-year mortality; diagnostic performance of the CCI was compared against our hyperkalemia model. The AKI subgroup was constituted of those meeting RIFLE criteria [14] (50% reduction in baseline eGFR). Severe AKI was defined as the need for initiation of hemodialysis or continuous renal replacement therapies.
Statistical methods
All covariates were assessed at initial ED evaluation. Baseline characteristics of patients were compared based on case or control status and K + levels at admission using standard statistical methods (Appendix III). Kaplan-Meier curves and log-ranks were used to compare survival times stratified by case control status, K + level, MDRD, and HF status.
Age and sex adjusted cumulative mortality rates were calculated for both cases and controls. After confirming the veracity of the proportionality hazards assumption, we used sex-pooled multivariable Cox proportional hazards regression models to relate concentrations of K + at admission to mortality [15] . C-statistic was used to examine the predictive utility of the Cox models [16] .
To assess for any potential nonlinearity of relations across values of potassium concentrations at admission, we used panelized cubic splines adjusting for age and sex [17] [18] [19] . Further analysis of renal function was conducted by stratifying subjects into ESRD and AKI subsets since admit GFR does not reflect dynamic changes in renal function. We studied a severe AKI subset defined as need for initiation of hemodialysis or continuous renal replacement therapy. All data analysis was performed using SAS software, Version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
A total of 14,483 patients presented to the ED during the study period. Evaluation of these consecutive episodes yielded 471 patients initially identified as hyperkalemia. 248 patients were excluded because of suspected or confirmed hemolysis, leaving 223 cases for analysis. 64 unmatched controls were randomly selected from those with confirmed hemolysis ( Figure 2 shows the increased risk of death with increasing potassium category based on potassium level at admission.
A positive linear trend in hazards ratios for mortality was observed between potassium level and CCI (p=0.07) ( Table 1 , online supplement). Statistically significant negative linear trend was observed with eGFR (p=0.001) ( Table 3) .
Three hierarchical Cox proportional hazard regression models are displayed in Table 2 Baseline characteristics of patients (n=287) according to admission potassium levels (mEq/L).
Kaplan-meier plot of time to death cases vs. controls.
Figure 1
Kaplan-meier plot of time to death by potassium level at admission.
Figure 2
restricted to 1-year follow-up. Model 1 was age and sex only adjusted; Model 2 was adjusted for the covariates that attained statistical significance in age and sex adjusted model; and Model 3 was additionally adjusted for CCI. The HRs and 95% CIs shown in Table 4 represent changes in HRs for every unit increase in raw potassium, log-potassium, and per 1-SD increase in log potassium, respectively. For each 1-unit (1 mEq/L) increase in potassium, the HR for mortality increased by 54% (HR: 1.54, 95% CI: 1.22-1.96) . The HRs and respective c-statistic were unchanged upon additional adjustment for CCI or upon log-transforming the potassium concentration. Compared to the lowest quartile of potassium, the second quartile had nearly twice the hazard for mortality (HR: 1.94, 95% CI: 1.03-3.64) and the 4 th quartile nearly 3.5 times the hazard (HR: 3.48, 95% CI: 1.78-6.81), therefore suggesting a nonlinear relationship with increasing potassium levels. The non-linear relationship of mortality hazard with increasing potassium concentrations was examined using cubic splines (Figure 3, online supplement) .
The HRs for respective potassium quartiles were qualitatively unchanged upon additional adjustment for CCI severity. In the landmark analysis, the same pattern that was observed in the overall analysis emerged even though the HRs were moderately higher. The HR associated with each 1-unit increase in potassium was 1.83 (95% CI: 1.38-2.44) ( Table 4 ). The HRs for parallel analyses using CCI as the exposure variable instead of potassium concentration ( Table 1 , online supplement) reveal that CCI was significantly associated with mortality in age and sex only adjusted models; in the overall analysis the associations become somewhat attenuated upon additional adjustment and did not attain statistical significance in the landmark analysis. Each 1-unit increase in CCI increased the hazard for mortality by 10% (HR: 1.10, 95% CI: 1.02-1.18).
The HRs using MDRD-GFR as the exposure variable (Table 3) revealed a significant protective effect; for each 1-unit increase in MDRD-GFR, the hazard for mortality decreases by 1%. Similar results were observed in the landmark analysis. The protective effect of MDRD-GFR was more pronounced in the third and fourth quartiles relative to the first quartile (HR: 0.59, 95% CI: 0.35-0.99 for 3 rd quartile: 0.35, 95% CI: 0.18-0.69 in the highest quartile). Kaplan-Meier curves showed that overall survival probability declined with decreasing MDRD-GFR at admission (log-rank p-value<0.0001) (Figure 2, online supplement) . The non-linear pattern of the HRs with increasing MDRD-GFR was examined using cubic splines (Figure 4 , online supplement).
Excess 1-year mortality was seen in the HF patients with hyperkalemia (58.3% versus 17.5% in controls with HF, log-rank p-value=0.03). Overall survival probability differed significantly between HF patients and those with no history of HF (log-rank p-value<0.0001) (Figure 4) .
To explore the joint relationship of potassium and MDRD-GFR, we used the composite outcome based on the 80 th percentile of admit potassium (6.1 mEq/L) and 20 th percentile of MDRD-GFR (15.11 ml/min). The Kaplan-Meier plots of the four composite categories showed a statistically significant difference (log-rank test p-value<0.0001) (Figure 1, online supplement) Kaplan-Meier survival curves showed statistically significantly better survival in ESRD patients compared to severe AKI patients (log-rank p-value=0.04). Overall survival in ESRD patients was 37.6% compared to severe AKI group 22.5% (n=32 ESRD patients vs. n=15 severe AKI patients). Mortality rate was 68.8% in AKI patients vs. 43.2% in non-AKI patients for overall follow-up time (log-rank p=0.01) (Figure 5, online supplement) .
Discussion
There are no intermediate and long-term mortality studies on the impact of single episode of hyperkalemia in the ED or general population. The current literature focuses largely on acute Table 4 Cox proportional hazard models examining the relations of potassium levels (mEq/L) to mortality. mortality of hyperkalemia. Cross-sectional analyses using large databases have shown increased mortality with hyperkalemia [1, 20] . Few studies on hospitalized hyperkalemic patients studied short term mortality [21] . To our knowledge, there is no longitudinal study or follow-up studies on ED hyperkalemic patients. Furthermore, the predictors for long term mortality in survivors from index hyperkalemia have not been studied. Identification of these predictors will help to target high risk mortality groups with novel therapeutic agents [5, 6] .
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In our study, the deleterious effect of admit hyperkalemia on allcause mortality even after discharge from index ED hyperkalemia was evident. More than 3 out of 4 deaths in cases occurred after discharge from index ED episode. This effect was especially marked in cases with HF who had a 58.3% 1-year mortality rate compared to 17.5% in controls with HF, in contrast to the expected 1-year mortality (30-40%) in HF patients in USA surviving hospitalization [22] .
The hazard ratios for mortality associated with admit potassium were higher, compared to the hazards associated with validated CCI. Renal function as estimated by MDRD GFR at admit, had significant protective effect on mortality. The dynamic changes in renal function as studied by AKI and severe AKI subsets had a greater role on all-cause mortality compared to static value of admit eGFR. Interestingly ESRD patients had better survival compared to severe AKI, perhaps owing to the effect of physiologic adaptations to repeated episodes of hyperkalemia [23] .
Hyperkalemia plays a significant role in certain CV disease [24] and is major factor affecting 30 day mortality and ventricular arrhythmias in Acute Myocardial Infarction [25] with a U-shaped relation of serum potassium with short term mortality/ arrhythmias especially with serum potassium of above 4.5 mEq/L [25] . This finding substantiates our hypothesis that myocardium may be more susceptible to hyperkalemia, especially in acute myocardial infarction and possibly in HF.
In the context of acute myocardial infarction, two studies shed light on long term mortality implications of serum potassium levels > 4.5 mEq/L. Shiyovich et al. showed that potassium >4.5 mEq/L is significantly associated with increased post-discharge long-term mortality in acute MI over median follow up of 8.1 years [26] . A similar study Choi et al showed mortality risk was greater for serum potassium >4.5 mEq/L (HR1.71, 95% [CI] 1.04 to 2.81 4.5 to <5.0 mEq/L and HR 4.78, 95% CI 2.14 to 10.69 for >5.0 when compared to patients with potassium levels of 3.5 to <4.0 mEq/L over mean of 3.58 year follow-up [27] .
These two studies however include acute myocardial infraction subjects only and not applicable to general population. Our study is the only one to our knowledge which studied long term outcomes of single episode of hyperkalemia in a population of heterogeneous subject who presented to Emergency department and likely representative of general population.
A few studies on the CKD population have showed a U shaped relationship between serum potassium and mortality. Serum potassium >5.0 mmol/L was associated with increased mortality in non-dialysis dependent CKD patients [28] . A secondary analysis of the Renal Research Institute study CKD cohort also showed an increased risk of the composite of death or cardiovascular events requiring hospitalization but no increase in overall mortality with serum potassium >5.5 mmol/L [29] . These studies are limited to CKD subjects only.
The mortality observed in the HF subset may be attributed to cardiac arrhythmias [30] . Hyperkalemia may be a surrogate marker for mortality or decompensated HF. Our findings are in contrast with short term data from inpatients (21) where HF was not a major predictor of short term mortality. The myocardium in advanced CKD non ESRD patients may be more sensitive to arrhythmogenic effects of hyperkalemia secondary to increased left ventricular mass or scarring. Current literature points to low GFR or reduced renal function as an independent risk factor for cardiac arrhythmias in varied populations [30, 31] and increased mortality among patients with implantable cardiac defibrillators [32] . This interaction between low GFR and HF in the hyperkalemic patient needs to be further explored. Renal function is a risk factor for increased mortality in HF patients [33, 34] and fatal cardiovascular disease in older patients [35] .
Our study findings show concurrence with the findings of Jain et al. [18] on patients with cardiovascular disease (defined in the study as hypertension and heart failure) and associated CKD where predictors of all-cause mortality included CKD stage (odds ratio [OR]: 1.26) and hyperkalemic event (>5 mEq/l) [OR: 1.56]. but follow up period was not specified.
Even mild hyperkalemia may predispose cardiovascular disease patients with impaired renal function to higher mortality as shown in our study. These data suggest that patients with hyperkalemia and concurrent HF, AKI, or low admit eGFR may need close monitoring and these patients need to be identified as high risk patients for interventions to prevent or treat hyperkalemia, especially after discharge from ED.
The persistence of the mortality risk after hyperkalemic episode is the high light of our study and calls for closer monitoring and intervention possibly with newer therapies in the followup period. Future studies are needed to explore the mortality benefits of new hyperkalemia therapies [5, 6] .
Limitations
Our study is inherently limited by its retrospective, single center design and that the cases were not individually matched to the controls which may cause residual confounding. Our study excluded patients with confirmed hemolysis (pseudohyperkalemia), and controls were derived from that population. Limited data on hemolysis incidence is available in the exiting literature. We paid meticulous attention to hemolysis maintaining the separation between cases and controls throughout the study period and up to 6 months later. Although our analysis has the significant advantage of being a clean database for studying true hyperkalemia, local variation in the accuracy of potassium measurements may limit the generalization of these results. The findings pertain to ED patients and may not be applicable to the general population.
Conclusions
Hyperkalemia was a strong predictor for all-cause mortality especially over the longer term, in the heterogeneous ED patient population even when adjusted for age, sex, Charlson comorbidity index, and significant covariates on univariate analysis, HF and ESRD. Excess hazards for all-cause mortality persisted thought out the follow up study period of 490 patient years in survivors from the index episode. Cardiovascular mortality was statistically more prevalent in hyperkalemic patients. Initial hyperkalemia was a stronger predictor for all-cause mortality than Charlson comorbidity index. Admit GFR had a protective non-linear effect on mortality. HF patients with hyperkalemia had higher risk of mortality.
The persistence of the mortality risk after hyperkalemic episode in our study calls for evolution of risk stratification strategies for hyperkalemia on the longer term, need for future studies to evaluate the mortality benefits of new hyperkalemia therapies [6] so as to evolve strategies that benefit higher risk mortality patients. Our study is a vital step in the identification of high risk mortality patients and evaluate the longer term mortality implications of hyperkalemia.
